Therefore, therapies targeting TTC13 as well as IL6-JAK-STAT3 signaling pathway may benefit ccRCC patients by simultaneously suppressing tumor cell growth and stimulating anti-tumor immunity. This evidence concerns the gene STAT3 and neoplasm.